Hernâni Oliveira Ph.D., a molecular oncologist, health communicator, digital media researcher, and grand prize winner of the Astellas 2017 C3 (Changing Cancer Care) Grand Prize discusses an augmented reality app to help solve common issues faced by pediatric patients and their parents around education and physical engagement.
Yale S. Hauptman, Esq, founding partner, Hauptman & Hauptman, PC, and Laurie A. Hauptman, Partner, Hauptman & Hauptman, PC., discuss elder law as it applies to medical special needs, long term care, financial issues, government benefits, and more.
Donna R. Cryer, JD, CEO of the Global Liver Institute and Wayne Eskridge, Founder, and CEO of the Fatty Liver Foundation, discuss nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)
Dr. Laurie LaPat-Polasko, Microbiologist and Vice President/National Director of Remediation for Matrix New World Engineering, discusses contaminants that affect our planet, clean water supply, and how it affects our health.
Nima Nejad Shiraz, VP of Finance & Operations at Tribeca Companies and COO with Spot-On Sciences, discusses the next generation of Dried Blood Spot (DBS) sample collection, and their partnering with Tribeca Companies to conduct an expansion of the company’s activities into new global markets.
As of June 11, 2019, Merck’s KEYTRUDA is now FDA approved for first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma as monotherapy for patients whose tumors express PD-L1 (CPS ≥1) or in combination with platinum and fluorouracil (FU) regardless of PD-L1 expression. Returning guest Dr. Danny Rischin, Director of the Department of Medical Oncology, Peter MacCallum Cancer Centre (Melbourne, Australia) discusses the final analysis of the Phase 3 KEYNOTE-048, KEYTRUDA study, which was presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
Dr. Gerard Clum, D.C., Board Member of the Foundation for Chiropractic Progress, addresses the issues surrounding neck manipulation and strokes. There have been numerous medical studies showing there is no causal link between strokes and chiropractic care. The latest study, published in the Annals of Medicine on April 6, 2019, concludes that “manual therapy does not result in an increased risk of cervical artery dissection or CAD.
Dr. Paul MacKoul, one of the founders of The Center for Innovative GYN Care® (CIGC), discusses recent research that showed complex GYN issues are going undiagnosed among women around the world. The study, conducted by CIGC, collected 5 years of data from over 1,500 hysterectomy patients and nearly 1 thousand myomectomy patients who had surgeries at CIGC. He also talks about the laparoscopy techniques, DualPortGYN® and LAAM-BUAO® that have been perfected by CIGC.
Doron Youngerwood, Director of Marketing at SysAid® Technologies, discusses their IT service management (ITSM) solution software that provides a suite of tools that increases efficiency and improves patient care.
Mike Davis, Head of Neurology for UCB, a global biopharmaceutical company in the U.S., discusses the recent FDA approval of NAYZILAM® (midazolam) for the short term nasal treatment of seizure clusters, the company’s seizure portfolio, and the company’s commitment to the epilepsy community.